Roy Herbst discusses the Zodiac trial, a phase 3 study assessing the efficacy of vandetanib for treating advanced non-small-cell lung cancer.Continue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv